Citigroup Downgrades Hims & Hers Health to Neutral, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Daniel Grosslight has downgraded Hims & Hers Health (NYSE:HIMS) from Buy to Neutral, while raising the price target from $16 to $20.

May 22, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Citigroup analyst Daniel Grosslight downgraded Hims & Hers Health from Buy to Neutral, but raised the price target from $16 to $20.
The downgrade from Buy to Neutral suggests a less optimistic outlook on the stock's performance, which could lead to a neutral or slightly negative short-term impact. However, the raised price target to $20 indicates some underlying confidence in the company's value, balancing the overall impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100